Background:ClinicaltestingtodetermineasuitabledoseoflinaclotideforJapanese
| INTRODUCTION
8.7%-8.9%).
3 Irritablebowelsyndromegreatlydisturbsqualityoflife (QOL)ofpatients. 4 IndividualswithIBSincurdirectandindirectcosts up to approximately 1.4 times that of healthy control individuals.
5
Irritablebowelsyndromeisalsoassociatedwithsubstantialcoststo healthcare systems and society. 6 Developingeffectivetreatmentfor IBSisbeneficialnotonlytoindividualsbutalsotothesociety.
Recent therapeutic strategies for IBS greatly focuses on differential treatments among subtypes of IBS. 7 Based on the Rome IV criteria, 2 thesesubtypesareIBSwithpredominantdiarrhea(IBS-D),
IBS with predominant constipation (IBS-C), IBS with mixed bowel habits(IBS-M),andIBSunclassified(IBS-U).Amongthesesubtypes, IBS-Cisrelativelyprevalentamonggeographicregions,rangingfrom
12.7%forAsia,13.6%forNorthAmerica/WesternEurope/Australia/ New Zealand, 39.4% for Latin America, to 43.3% for the Middle East. 3 Japanese epidemiologic survey showed that constipation increases risk of mortality due to cardiovascular disease. Linaclotide is a 14-amino acid peptide that activates the guanylatecyclaseC(GC-C)receptorlocatedintheapicalcellmembrane ofthegutepithelium. 9, 10 ActivationofGC-Cresultsintheproduction andreleaseofincyclicguanosinemonophosphate(cGMP)inenterocytes. Intracellular cGMP results in increased secretion of chloride ion and bicarbonate ion into the intestinal lumen and concomitant fluid secretion. [11] [12] [13] Distinct benefits of linaclotide were shown in patientswithIBS-C. 14 
| METHODS

| Patient population
Key Points
• LinaclotideisapprovedforIBSwithconstipation(IBS-C) inwesterncountriesatadoseof0.29mg.
• AphaseIIdose-findingtrialinJapanrevealedthat0.5mg/ dayoflinaclotidewasmosteffectiveonglobalimprovement,completespontaneousbowelmovement,andabdominalpain/discomfortinIBS-Cpatients.
• Thefindingofthisstudygivesusagreathintofhowguanylate cyclase C receptor activator works in IBS-C patientswithdifferentgenes,diet,gutmicrobiota,orother factors. 
| Study design
| Data collection
During the pretreatment and treatment periods, patients recorded their IBS symptoms every day in a paper diary at bedtime and with eachbowelmovement,andsubsequentlyelectronicallyenteredthese data into a database daily using an interactive voice response system.
ThissystemofevaluatingIBSsymptomshasbeenpreviouslyreported
as reliable and valid. 
| Efficacy and safety endpoints
The primary endpoint was responder rate of the global assessment of relief of IBS symptoms during 12weeks. Patients with assessmentof1or2foraweeklyevaluationpointweredefinedasweekly responders, and patients who were weekly responders for at least 6 of the 12weeks were considered to be overall responders. The PharmaceuticalsandMedicalDevicesAgencyapproveduseofglobal assessmentofreliefofIBSsymptomsasaprimaryendpointforIBS studies.
23,24
Secondary endpoints included relief of abdominal pain/ discomfort,improvementinabnormalbowelhabits,stoolfrequency, SBMresponder,CSBMresponder,stoolconsistency,severityofabdominalpain/discomfort,straining,andIBS-QOL.Weeklyresponders of abdominal pain/discomfort relief or abnormal bowel habits improvement were defined as patients with a score of 1 or 2 ranging from 1 to 7 at the weekly evaluation point and patients who were weeklyrespondersforatleast6ofthe12weekswereconsideredto beoverallresponders.WeeklyrespondersofSBMorCSBMwerede-
the12weekswereconsideredtobeoverallresponders.Alladverse events were recorded during the treatment period.
| Statistical analysis
Statistical analysis was performed using SAS Drug Development (ver.3.4)andPC-SAS(ver.9.1.3;SASInstituteInc.,Cary,NC,USA). Efficacyanalyseswereperformedonthefullanalysisset,which wasascompleteaspossibleandascloseaspossibletotheintentionto-treat (ITT) ideal of including all randomized subjects. 27 The full analysissetincludedallpatientswhoreceivedatleast1doseofthe study drug during the treatment period and in whom more than 1 endpoint could be evaluated. To determine the robustness of the results,primaryanalyseswerealsoperformedaccordingtotheperprotocolsetdefinedassubsetofthesubjectsinthefullanalysisset whocompletedtheprotocol.Safetyanalyseswereperformedforall patients who received at least 1 dose of the study drug during the treatment period.
As ad hoc additional efficacy analysis, weekly responders of CSBM+1 and abdominal pain/discomfort severity score were definedaspatientswithincreasein≥1CSBMandadecreasein≥30% in abdominal pain/discomfort score from baseline at each weekly evaluationpointrespectively.Weeklyrespondersoftheseevaluation items for at least 6 of the 12weeks were considered to be overall responders, referring to FDA guidance. 7 Composite responder rate was the proportion of patients who had a composite response of both CSBM+1 and abdominal pain/discomfort severity score,which wasreferringtothecompositeresponderdefinedbyFDAguidance. 
| RESULTS
| Overall study population
Among patients who provided written informed consent (n=1276), 
| Evaluation of the primary endpoint
| Safety
| DISCUSSION
The results of this trial on the treatment of IBS-C patients in Japan withlinaclotidesupportsanoptimaldoseof0.5mg/daywhichisdifferent from the dose approved for this indication in the US and EU (0.29mg/day). 15, [17] [18] [19] We judged linaclotide 0.5mg/day to be opti- We tried to provide an explanation for the difference in optimal doseinJapancomparedtoUSandEU.LinaclotideactivatestheGC-C receptorlocatedintheapicalmembraneoftheepithelialcellsofthe gut.
9,10
This activation causes accumulation of intracellular cGMP in the gut epithelium.
Thus,chlorideionsandbicarbonateionaresecretedintotheintestinallumenwithconcomitantsecretionoffluid.
11-
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The GC-C receptor has a genetic polymorphism associated with attention deficit/hyperactive disorder 29, 30 which is highly comorbid with pediatric constipation. Further study is necessary to clarify this relation between GUCA2A geneandintraluminalguanylineffect.
Diet is also very different between western countries and Japan.
20
Americans consume more fat in their diet (https://www.
ars.usda.gov/northeast-area/beltsville-md/beltsville-human-nutrition-research-center/food-surveys-research-group/docs/ wweia-data-tables/) than Japanese (http://www.mhlw.go.jp/bunya/ kenkou/kenkou_eiyou_chousa.html). Diet-induced obesity causes a loss of guanylin expression in the colon with subsequent GUCY2C
silencing.
34
Therefore,Japanesedietmayinducemoreexpressionof intraluminal guanylin than western diet. The gut microbiota is also very different between western countries and Japan. 35 Not only guanylin-family hormones but also heat-stable enterotoxins which are produced by enterotoxigenic Escherichia coli bind to GC-C receptors.
32
Thegutmetagenomeanalysesshowedthatporphyranases and agarases are frequent in theJapanese population and that they are absent in metagenome data from North American individuals.
36
ItispossiblethatthenaturalligandsforGC-Creceptorsproducedby gutmicrobiotainJapanesepatientsactascompetitorsoflinaclotide.
Linaclotideisstableintheacidicenvironmentofthestomachandis convertedtothemetaboliteMM-419447inthesmallintestine.
33
The disulfide bonds of both peptides are reduced in the small intestine, where they are subsequently proteolyzed and degraded. This study has some limitations. Firstly, the primary endpoint of this study was not significant when adjusted for multiplicity. of0.5mgmaybeappropriateinJapanesepatientswithIBS-C.
